These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38133557)

  • 41. Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y;
    Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):698-706. PubMed ID: 35170529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased Spleen Volume in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab in Comparison to Lenvatinib: A Retrospective Analysis.
    Hatanaka T; Naganuma A; Furusawa A; Tamura Y; Saito N; Suzuki Y; Hoshino T; Yata Y; Uraoka T; Kakizaki S
    Oncology; 2023; 101(3):193-202. PubMed ID: 36649691
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Classification and Regression Trees to Predict for Survival for Patients With Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.
    Brown TJ; Gimotty PA; Mamtani R; Karasic TB; Yang YX
    JCO Clin Cancer Inform; 2024 Aug; 8():e2300220. PubMed ID: 39088775
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
    Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Yokohama K; Nishikawa H; Nishimura T; Shimada N; Kawata K; Kosaka H; Naganuma A; Yata Y; Ohama H; Kuroda H; Aoki T; Tanaka K; Tanaka T; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M; Kumada T;
    Hepatol Res; 2024 Apr; 54(4):382-391. PubMed ID: 37983642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
    Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
    JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis.
    Hatanaka T; Naganuma A; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Kakizaki S; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kumada T;
    Cancer Med; 2023 Feb; 12(4):4259-4269. PubMed ID: 36156452
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Matono T; Kuroda H; Yata Y; Ohama H; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Yokohama K; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; ;
    Oncology; 2023; 101(10):624-633. PubMed ID: 37307798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.
    Tsilimigras DI; Moris D
    J BUON; 2021; 26(2):637. PubMed ID: 34077021
    [No Abstract]   [Full Text] [Related]  

  • 49. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging.
    Yegin EG; Siykhymbayev A; Eren F; Bekiroglu N; Ozdogan OC
    Ann Hepatol; 2013; 12(6):915-25. PubMed ID: 24114822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants.
    Nakabori T; Kunimasa K; Kawabata M; Higashi S; Mukai K; Kawamura T; Inoue T; Tamiya M; Nishino K; Ohkawa K
    Cancer Med; 2024 Jun; 13(12):e7430. PubMed ID: 38924675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
    Ohama H; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Matono T; Shibata H; Aoki T; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kudo M; Kumada T; ;
    Oncology; 2023; 101(9):542-552. PubMed ID: 37552968
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.
    Tada T; Kumada T; Hiraoka A; Kariyama K; Tani J; Hirooka M; Takaguchi K; Atsukawa M; Fukunishi S; Itobayashi E; Tsuji K; Tajiri K; Ochi H; Ishikawa T; Yasuda S; Ogawa C; Toyoda H; Hatanaka T; Nishimura T; Kakizaki S; Kawata K; Shimada N; Tada F; Nouso K; Tsutsui A; Ohama H; Morishita A; Nagano T; Itokawa N; Okubo T; Arai T; Kosaka H; Imai M; Naganuma A; Nakamura S; Koizumi Y; Kaibori M; Iijima H; Hiasa Y;
    Cancer Med; 2023 Mar; 12(6):6980-6993. PubMed ID: 36484470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
    World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture.
    Miyata T; Sugi K; Horino T; Ono A; Tagayasu Y; Nomoto D; Inoue M; Mizumoto T; Kubota T; Yanagida E; Murayama T; Miyanari N; Baba H
    Anticancer Res; 2023 Feb; 43(2):943-947. PubMed ID: 36697062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
    Eso Y; Takeda H; Taura K; Takai A; Takahashi K; Seno H
    Curr Oncol; 2021 Oct; 28(5):4157-4166. PubMed ID: 34677270
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    Yamauchi R; Ito T; Yoshio S; Yamamoto T; Mizuno K; Ishigami M; Kawashima H; Yasuda S; Shimose S; Iwamoto H; Yamazoe T; Mori T; Kakazu E; Kawaguchi T; Toyoda H; Kanto T
    J Gastroenterol; 2023 Jun; 58(6):565-574. PubMed ID: 36991155
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Ohama H; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kudo M; ;
    Oncology; 2022; 100(12):645-654. PubMed ID: 36103846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma.
    Huang Z; Chen T; Li W; Qiu J; Liu S; Wu Z; Li B; Yuan Y; He W
    Clin Exp Med; 2024 Jun; 24(1):138. PubMed ID: 38940944
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
    Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.